Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes

What Was Tested

The paper reports a study of Glucagon and ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

The researchers examined the effects of acute and 21-day administration of liraglutide on plasma atrial natriuretic peptide (ANP), urinary sodium excretion, office and 24-h BP, and heart rate (HR).

Who Took Part

The study group was 3 subjects.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.

Simultaneous 24-h ambulatory BP and HR monitoring and 24-h urine collections were measured at baseline and following 21 days of treatment.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 3 weeks.

What Was Measured

PubMed files the paper under topics including Atrial Natriuretic Factor, Blood Pressure, Diabetes Mellitus, Type 2, Endpoint Determination, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and ANP (Atrial Natriuretic Peptide) in 3 subjects over 3 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page and the ANP (Atrial Natriuretic Peptide) compound page.